Physician profile
Dylan West
NPI 1508333790
$4,414.95
in general payments reported to CMS, 2019-2025
13 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $368 · 2024: $2,004 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,234 · Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,233.51 |
| Food and Beverage | $1,181.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,256.99 | 2023-2025 | Illumisite |
| Intuitive Surgical, INC. | $531.42 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $158.57 | 2023-2025 | Tezspire, Airsupra |
| Inari Medical, INC. | $141.60 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Glaxosmithkline, LLC. | $67.59 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Haemonetics Corporation | $54.68 | 2023 | Teg6s Hemostasis System |
| United Therapeutics Corporation | $51.46 | 2024 | Tyvaso |
| Ethicon INC. | $39.79 | 2025 | Monarch Platform |
| Shionogi INC | $38.05 | 2023-2025 | Fetroja |
| Genzyme Corporation | $21.12 | 2024 | |
| Abbvie INC. | $19.29 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.42 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $15.97 | 2024 | Recarbrio, Dificid, Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.